{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T05:17:16Z","timestamp":1780377436417,"version":"3.54.1"},"reference-count":136,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.autrev.2022.103264","type":"journal-article","created":{"date-parts":[[2022,12,19]],"date-time":"2022-12-19T20:18:23Z","timestamp":1671481103000},"page":"103264","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["The role of bDMARDs in idiopathic inflammatory myopathies: A systematic literature review"],"prefix":"10.1016","volume":"22","author":[{"given":"Silvia","family":"Grazzini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Rizzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edoardo","family":"Conticini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"D'Alessandro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lidia","family":"La Barbera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriana","family":"D'Alessandro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Falsetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Bargagli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuliana","family":"Guggino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Cantarini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Frediani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.autrev.2022.103264_bb0005","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/nrrheum.2018.41","article-title":"Classification of myositis","volume":"14","author":"Lundberg","year":"2018","journal-title":"Nat Rev Rheumatol"},{"issue":"7","key":"10.1016\/j.autrev.2022.103264_bb0010","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1056\/NEJM197502132920706","article-title":"Polymyositis and dermatomyositis (first of two parts)","volume":"292","author":"Bohan","year":"1975","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.autrev.2022.103264_bb0015","first-page":"269","article-title":"Polymyositis and dermatomyositis (second of two parts)","volume":"292","author":"B. A and P. JB","year":"1975","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.autrev.2022.103264_bb0020","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1056\/NEJM199111213252107","article-title":"Polymyositis, dermatomyositis and inclusion-body myositis","volume":"325","author":"Dalakas","year":"1991","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.autrev.2022.103264_bb0025","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1097\/00005792-199111000-00002","article-title":"A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogeneous patient groups","volume":"70","author":"Love","year":"1991","journal-title":"Medicine"},{"issue":"5","key":"10.1016\/j.autrev.2022.103264_bb0030","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.nmd.2004.02.006","article-title":"119th ENMC international workshop: trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, 10-12 October 2003, Naarden, the Netherlands","volume":"14","author":"Hoogendijk","year":"2004","journal-title":"Neuromuscul Disord"},{"issue":"12","key":"10.1016\/j.autrev.2022.103264_bb0035","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1136\/annrheumdis-2017-211468","article-title":"2017 European league against rheumatism\/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups","volume":"76","author":"Lundberg","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.autrev.2022.103264_bb0040","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/nrrheum.2018.56","article-title":"Autoantibodies in myositis","volume":"14","author":"McHugh","year":"2018","journal-title":"Nat Rev Rheumatol"},{"issue":"3","key":"10.1016\/j.autrev.2022.103264_bb0045","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1007\/s10067-020-05273-3","article-title":"Myositis-specific autoantibodies in adults with idiopathic inflammatory myopathy: correlations with diagnosis and disease activity","volume":"40","author":"Zhao","year":"2021","journal-title":"Clin Rheumatol"},{"issue":"1","key":"10.1016\/j.autrev.2022.103264_bb0050","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41572-021-00321-x","article-title":"Idiopathic inflammatory myopathies","volume":"7","author":"Lundberg","year":"2021","journal-title":"Nat Rev Dis Primers"},{"issue":"7","key":"10.1016\/j.autrev.2022.103264_bb0055","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1080\/1744666X.2018.1491307","article-title":"Treatment of inflammatory myopathies","volume":"14","author":"Pipitone","year":"2018","journal-title":"Expert Rev Clin Immunol"},{"issue":"6","key":"10.1016\/j.autrev.2022.103264_bb0060","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1097\/BOR.0000000000000745","article-title":"Up-to-date treatment and management of myositis","volume":"32","author":"Pipitone","year":"2020","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.autrev.2022.103264_bb0065","doi-asserted-by":"crossref","DOI":"10.1177\/1759720X221100299","article-title":"A glance into the future of myositis therapy","volume":"14","author":"Chiapparoli","year":"2022","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"10.1016\/j.autrev.2022.103264_bb0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.coph.2022.102257","article-title":"Current and new targets for treating myositis","volume":"65","author":"Moghadam-Kia","year":"2022","journal-title":"Curr Opin Pharmacol"},{"issue":"7","key":"10.1016\/j.autrev.2022.103264_bb0075","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1517\/13543784.10.7.1265","article-title":"Recent advances in the management of adult myositis","volume":"10","author":"Fam","year":"2005","journal-title":"Expert Opin Investig Drugs"},{"issue":"4","key":"10.1016\/j.autrev.2022.103264_bb0080","first-page":"277","article-title":"IMAJ | The Israel Medicine Association Journal | Volume, Number 4, April 2008 | Anti-Tumor Necrosis Factor Therapy: 6 Year Experience of a Single Center in Northern Israel and Possible Impact of Health Policy on Results","volume":"10","author":"Braun-Moscovici","year":"2008","journal-title":"Isr Med Assoc J"},{"issue":"9","key":"10.1016\/j.autrev.2022.103264_bb0085","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1136\/ard.2005.048744","article-title":"Possible role for tumour necrosis factor inhibitors in the treatment of resistant dermatomyositis and polymyositis: a retrospective study of eight patients","volume":"65","author":"Efthimiou","year":"2006","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.autrev.2022.103264_bb0090","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1093\/rheumatology\/keh062","article-title":"Treatment of myositis with etanercept (Enbrel), a recombinant human soluble fusion protein of TNF-alpha type II receptor and IgG1","volume":"43","author":"Sprott","year":"2004","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"10.1016\/j.autrev.2022.103264_bb0095","doi-asserted-by":"crossref","first-page":"S139","DOI":"10.1016\/j.jaad.2005.11.1090","article-title":"Case reports of etanercept in inflammatory dermatoses","volume":"54","author":"Norman","year":"2006","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"10.1016\/j.autrev.2022.103264_bb0100","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1007\/s00296-008-0695-4","article-title":"Necrotizing fasciitis in a patient treated with etanercept for dermatomyositis","volume":"29","author":"Choi","year":"2009","journal-title":"Rheumatol Int"},{"issue":"2","key":"10.1016\/j.autrev.2022.103264_bb0105","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.autrev.2008.05.002","article-title":"Treatment with etanercept in six patients with chronic hepatitis C infection and systemic autoimmune diseases","volume":"8","author":"Cavazzana","year":"2008","journal-title":"Autoimmun Rev"},{"issue":"9","key":"10.1016\/j.autrev.2022.103264_bb0110","first-page":"1802","article-title":"Use of etanercept in the treatment of dermatomyositis: a case series","volume":"33","author":"Iannone","year":"2006","journal-title":"The Journal of Rheumatolog"},{"issue":"3","key":"10.1016\/j.autrev.2022.103264_bb0115","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1002\/ana.22477","article-title":"A randomized, pilot trial of etanercept in dermatomyositis","volume":"70","author":"Amato","year":"2011","journal-title":"Ann Neurol"},{"issue":"10","key":"10.1016\/j.autrev.2022.103264_bb0120","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1093\/rheumatology\/41.10.1194","article-title":"Non-Hodgkin\u2019s lymphoma in a patient with refractory dermatomyositis which had been treated with infliximab","volume":"41","author":"Roddy","year":"2002","journal-title":"Rheumatology (Oxford)"},{"issue":"4","key":"10.1016\/j.autrev.2022.103264_bb0125","doi-asserted-by":"crossref","DOI":"10.1111\/dth.14976","article-title":"The effects of infliximab in treating idiopathic inflammatory myopathies: a review article","volume":"34","author":"Ge","year":"2021","journal-title":"Dermatol Ther"},{"issue":"1","key":"10.1016\/j.autrev.2022.103264_bb0130","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-020-02164-5","article-title":"Retrospective analysis of infliximab and adalimumab treatment in a large cohort of juvenile dermatomyositis patients","volume":"22","author":"Campanilho-Marques","year":"2020","journal-title":"Arthritis Res Ther"},{"issue":"23","key":"10.1016\/j.autrev.2022.103264_bb0135","doi-asserted-by":"crossref","first-page":"3237","DOI":"10.2169\/internalmedicine.7966-16","article-title":"Hemophagocytic syndrome complicated with dermatomyositis controlled successfully with infliximab and conventional therapies","volume":"56","author":"Komiya","year":"2017","journal-title":"Intern Med"},{"issue":"46","key":"10.1016\/j.autrev.2022.103264_bb0140","doi-asserted-by":"crossref","first-page":"7425","DOI":"10.3748\/wjg.v26.i46.7425","article-title":"Infliximab is effective in the treatment of ulcerative colitis with dermatomyositis: a case report","volume":"26","author":"Huang","year":"2020","journal-title":"World J Gastroenterol"},{"issue":"3","key":"10.1016\/j.autrev.2022.103264_bb0145","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1159\/000510740","article-title":"Immune checkpoint inhibitor-induced polymyositis and myasthenia gravis with fatal outcome","volume":"13","author":"Giglio","year":"2020","journal-title":"Case Rep Oncol"},{"issue":"11","key":"10.1016\/j.autrev.2022.103264_bb0150","doi-asserted-by":"crossref","first-page":"3587","DOI":"10.1007\/s00296-011-2220-4","article-title":"Successful treatment for conventional treatment-resistant dermatomyositis-associated interstitial lung disease with adalimumab","volume":"32","author":"Park","year":"2012","journal-title":"Rheumatol Int"},{"issue":"4","key":"10.1016\/j.autrev.2022.103264_bb0155","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.jbspin.2012.10.012","article-title":"Adalimumab in anti-synthetase syndrome","volume":"80","author":"da Silva","year":"2013","journal-title":"Joint Bone Spine"},{"issue":"10","key":"10.1016\/j.autrev.2022.103264_bb0160","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1093\/rheumatology\/keu234","article-title":"A case of overlap syndrome successfully treated with tocilizumab: a hopeful treatment strategy for refractory dermatomyositis?","volume":"53","author":"Kondo","year":"2014","journal-title":"Rheumatology (Oxford)"},{"issue":"7","key":"10.1016\/j.autrev.2022.103264_bb0165","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1111\/ced.14325","article-title":"Successful treatment of dermatomyositis and associated calcinosis with adalimumab","volume":"45","author":"Xie","year":"2020","journal-title":"Clin Exp Dermatol"},{"issue":"7","key":"10.1016\/j.autrev.2022.103264_bb0170","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1093\/rheumatology\/ker152","article-title":"Therapeutic effect of tocilizumab on two patients with polymyositis","volume":"50","author":"Narazaki","year":"2011","journal-title":"Rheumatology"},{"issue":"7","key":"10.1016\/j.autrev.2022.103264_bb0175","doi-asserted-by":"crossref","first-page":"E227","DOI":"10.1093\/rheumatology\/keaa906","article-title":"Tocilizumab for refractory rapidly progressive interstitial lung disease related to anti-MDA5-positive dermatomyositis","volume":"60","author":"Zhang","year":"2021","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"10.1016\/j.autrev.2022.103264_bb0180","doi-asserted-by":"crossref","DOI":"10.1111\/dth.14712","article-title":"NXP2-positive dermatomyositis complicated with refractory skin edema: Successful treatment with tocilizumab","volume":"34","author":"Lu","year":"2021","journal-title":"Dermatol Ther"},{"issue":"2","key":"10.1016\/j.autrev.2022.103264_bb0185","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1080\/03009742.2021.1972519","article-title":"Tocilizumab and rituximab for anti-MDA-5 positive amyopathic dermatomyositis complicated with macrophage activation syndrome and progressive fibrosing interstitial lung disease","volume":"51","author":"Su","year":"2022","journal-title":"Scand J Rheumatol"},{"issue":"5","key":"10.1016\/j.autrev.2022.103264_bb0190","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1002\/art.41604","article-title":"Inflammatory myositis in Cancer patients receiving immune checkpoint inhibitors","volume":"73","author":"Aldrich","year":"2021","journal-title":"Arthritis Rheum"},{"issue":"12","key":"10.1016\/j.autrev.2022.103264_bb0195","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1093\/rheumatology\/kew296","article-title":"The successful use of tocilizumab as third-line biologic therapy in a case of refractory anti-synthetase syndrome","volume":"55","author":"Murphy","year":"2016","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2022.103264_bb0200","series-title":"Revue du Rhumatisme (Edition Francaise)","first-page":"78","article-title":"Un syndrome des antisynth\u00e9tases trait\u00e9 partocilizumab","volume":"83","author":"Beaumel","year":"2016"},{"key":"10.1016\/j.autrev.2022.103264_bb0205","series-title":"Randomized Trial of Tocilizumab in the Treatment of Refractory Adult Polymyositis and Dermatomyositis","author":"Oddis","year":"2022"},{"issue":"5","key":"10.1016\/j.autrev.2022.103264_bb0210","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1136\/annrheumdis-2012-202857","article-title":"Anakinra treatment in patients with refractory inflammatory myopathies and possible predictive response biomarkers: a mechanistic study with 12 months follow-up","volume":"73","author":"Zong","year":"2014","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.autrev.2022.103264_bb0215","first-page":"429","article-title":"Abatacept for treatment of refractory polymyositis","volume":"78","author":"Musuruana","year":"2011"},{"issue":"3","key":"10.1016\/j.autrev.2022.103264_bb0220","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1007\/s10067-014-2507-4","article-title":"Abatacept as a successful therapy for myositis\u2014a case-based review","volume":"34","author":"Kerola","year":"2015","journal-title":"Clin Rheumatol"},{"issue":"4","key":"10.1016\/j.autrev.2022.103264_bb0225","doi-asserted-by":"crossref","first-page":"618","DOI":"10.46497\/ArchRheumatol.2020.7406","article-title":"A case of refractory polymyositis successfully treated with Abatacept monotherapy","volume":"35","author":"\u00c7a\u011flayan","year":"2020","journal-title":"Arch Rheumatol"},{"issue":"1","key":"10.1016\/j.autrev.2022.103264_bb0230","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1136\/annrheumdis-2017-211751","article-title":"Abatacept in the treatment of adult dermatomyositis and polymyositis: a randomised, phase IIb treatment delayed-start trial","volume":"77","author":"Tj\u00e4rnlund","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2022.103264_bb0235","series-title":"A case report of immune checkpoint inhibitor-related steroid-refractory myocarditis and myasthenia gravis-like myositis treated with abatacept and mycophenolate mofetil","author":"Syberg Jespersen","year":"2022"},{"issue":"3","key":"10.1016\/j.autrev.2022.103264_bb0240","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1097\/RHU.0000000000000514","article-title":"Successful treatment of refractory juvenile dermatomyositis with adalimumab","volume":"23","author":"Wang","year":"2017","journal-title":"J Clin Rheumatol"},{"issue":"2","key":"10.1016\/j.autrev.2022.103264_bb0245","doi-asserted-by":"crossref","first-page":"457","DOI":"10.55563\/clinexprheumatol\/ltrj4l","article-title":"A systematic review on biological therapies in juvenile idiopathic inflammatory myopathies: an evidence gap in precision medicine","volume":"40","author":"Marrani","year":"2022","journal-title":"Clin Exp Rheumatol"},{"issue":"5","key":"10.1016\/j.autrev.2022.103264_bb0250","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1002\/acr.22198","article-title":"Pilot study of etanercept in patients with refractory juvenile dermatomyositis","volume":"66","author":"Rouster-Stevens","year":"2014","journal-title":"Arthritis Care Res"},{"issue":"1","key":"10.1016\/j.autrev.2022.103264_bb0255","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.pedneo.2014.02.006","article-title":"Juvenile dermatomyositis: a 20-year retrospective analysis of treatment and clinical outcomes","volume":"56","author":"Sun","year":"2015","journal-title":"Pediatr Neonatol"},{"issue":"3","key":"10.1016\/j.autrev.2022.103264_bb0260","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.jpeds.2011.11.057","article-title":"Abatacept and sodium thiosulfate for treatment of recalcitrant juvenile dermatomyositis complicated by ulceration and calcinosis","volume":"160","author":"Arabshahi","year":"2012","journal-title":"J Pediatr"},{"issue":"1","key":"10.1016\/j.autrev.2022.103264_bb0265","doi-asserted-by":"crossref","DOI":"10.1093\/rheumatology\/kew146","article-title":"Rituximab in the treatment of inflammatory myopathies: a review","volume":"56","author":"Fasano","year":"2017","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"10.1016\/j.autrev.2022.103264_bb0270","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1002\/art.37754","article-title":"Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial","volume":"65","author":"Oddis","year":"2013","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.autrev.2022.103264_bb0275","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s10067-021-05871-9","article-title":"Rituximab as a glucocorticoid-sparing agent in idiopathic inflammatory myopathies: a retrospective single-center cohort study","volume":"41","author":"Egeli","year":"2022","journal-title":"Clin Rheumatol"},{"issue":"12","key":"10.1016\/j.autrev.2022.103264_bb0280","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1093\/rheumatology\/ker305","article-title":"Efficacy and safety of rituximab in the treatment of refractory inflammatory myopathies in adults: results from the AIR registry","volume":"50","author":"Couderc","year":"2011","journal-title":"Rheumatology"},{"issue":"2","key":"10.1016\/j.autrev.2022.103264_bb0285","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1007\/s10067-013-2449-2","article-title":"Use of rituximab in histologically confirmed idiopathic inflammatory myositis: a case series","volume":"34","author":"Basnayake","year":"2015","journal-title":"Clin Rheumatol"},{"issue":"9","key":"10.1016\/j.autrev.2022.103264_bb0290","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1093\/rheumatology\/keu024","article-title":"Rituximab therapy in patients with refractory dermatomyositis or polymyositis: differential effects in a real-life population","volume":"53","author":"Unger","year":"2014","journal-title":"Rheumatology"},{"issue":"9","key":"10.1016\/j.autrev.2022.103264_bb0295","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1002\/art.38018","article-title":"Rituximab in refractory and relapsed dermatomyositis and polymyositis: comment on the article by oddis et al","volume":"65","author":"Cuttner","year":"2013","journal-title":"Arthritis Rheum"},{"issue":"5","key":"10.1016\/j.autrev.2022.103264_bb0300","first-page":"689","article-title":"Novel assessment tools to evaluate clinical and laboratory responses in a subset of patients enrolled in the rituximab in myositis trial","volume":"32","author":"Rider","year":"2014","journal-title":"Clin Exp Rheumatol"},{"issue":"6","key":"10.1016\/j.autrev.2022.103264_bb0305","first-page":"896","article-title":"Rituximab as an effective alternative therapy in refractory idiopathic inflammatory myopathies","volume":"31","author":"Mu\u00f1oz-Beamud","year":"2013","journal-title":"Clin Exp Rheumatol"},{"issue":"1\u20132","key":"10.1016\/j.autrev.2022.103264_bb0310","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.jns.2013.08.007","article-title":"The effect of anakinra, an IL1 receptor antagonist, in patients with sporadic inclusion body myositis (sIBM): a small pilot study","volume":"334","author":"Kosmidis","year":"2013","journal-title":"J Neurol Sci"},{"issue":"4","key":"10.1016\/j.autrev.2022.103264_bb0315","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000581","article-title":"Trial of canakinumab, an IL-1\u03b2 receptor antagonist, in patients with inclusion body myositis","volume":"6","author":"Kosmidis","year":"2019","journal-title":"Neurol Neuroimmunol Neuroinflammat"},{"issue":"12","key":"10.1016\/j.autrev.2022.103264_bb0320","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1136\/ard.2007.077974","article-title":"A high incidence of disease flares in an open pilot study of infliximab in patients with refractory inflammatory myopathies","volume":"67","author":"Dastmalchi","year":"2008","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.autrev.2022.103264_bb0325","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1097\/RHU.0000000000000430","article-title":"A rare case of amyopathic juvenile dermatomyositis associated with psoriasis successfully treated with ustekinumab","volume":"23","author":"Montoya","year":"2017","journal-title":"J Clin Rheumatol"},{"issue":"7","key":"10.1016\/j.autrev.2022.103264_bb0330","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1093\/rheumatology\/kez020","article-title":"Successful treatment of refractory mechanic\u2019s hands with ustekinumab in a patient with the antisynthetase syndrome","volume":"58","author":"Pinal-Fernandez","year":"2019","journal-title":"Rheumatology (Oxford)"},{"issue":"10","key":"10.1016\/j.autrev.2022.103264_bb0335","first-page":"1866","article-title":"The successful use of subcutaneous abatacept in refractory anti- human transcriptional intermediary factor 1-gamma dermatomyositis skin and oesphagopharyngeal disease","volume":"57","author":"Rodziewicz","year":"2018","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"10.1016\/j.autrev.2022.103264_bb0340","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1001\/archderm.143.6.763","article-title":"A pilot trial of rituximab in the treatment of patients with dermatomyositis","volume":"143","author":"Chung","year":"2007","journal-title":"Arch Dermatol"},{"issue":"1","key":"10.1016\/j.autrev.2022.103264_bb0345","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.jaad.2006.05.068","article-title":"Rituximab for the treatment of the skin manifestations of dermatomyositis: a report of 3 cases","volume":"56","author":"Dinh","year":"2007","journal-title":"J Am Acad Dermatol"},{"issue":"7","key":"10.1016\/j.autrev.2022.103264_bb0350","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.3899\/jrheum.101321","article-title":"Safety and efficacy of rituximab in severe juvenile dermatomyositis: results from 9 patients from the French autoimmunity and rituximab registry","volume":"38","author":"Bader-Meunier","year":"2011","journal-title":"J Rheumatol"},{"issue":"2","key":"10.1016\/j.autrev.2022.103264_bb0355","doi-asserted-by":"crossref","DOI":"10.1016\/j.berh.2022.101768","article-title":"Calcinosis in dermatomyositis: origins and possible therapeutic avenues","volume":"36","author":"Davuluri","year":"2022","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"10.1016\/j.autrev.2022.103264_bb0360","first-page":"1","article-title":"Abatacept in the treatment of juvenile dermatomyositis-associated calcifications in a 16-year-old girl","volume":"2020","author":"Sukumaran","year":"2020","journal-title":"Case Rep Rheumatol"},{"issue":"11","key":"10.1016\/j.autrev.2022.103264_bb0365","doi-asserted-by":"crossref","DOI":"10.1093\/brain\/awz293","article-title":"Treatment of anti-MDA5 autoantibody-positive juvenile dermatomyositis using tofacitinib","volume":"142","author":"Sabbagh","year":"2019","journal-title":"Brain."},{"issue":"6","key":"10.1016\/j.autrev.2022.103264_bb0370","first-page":"904","article-title":"Interleukin-1 receptor antagonist for refractory anti-MDA5 clinically amyopathic dermatomyopathy","volume":"33","author":"Groh","year":"2015","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.autrev.2022.103264_bb0375","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/1759720X211037519","article-title":"Natural history and screening of interstitial lung disease in systemic autoimmune rheumatic disorders","volume":"13","author":"Panagopoulos","year":"2021","journal-title":"Ther Adv Musculoskel Dis"},{"issue":"4","key":"10.1016\/j.autrev.2022.103264_bb0380","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.rmed.2012.01.001","article-title":"Rituximab therapy for refractory interstitial lung disease related to antisynthetase syndrome","volume":"106","author":"Marie","year":"2012","journal-title":"Respir Med"},{"issue":"6","key":"10.1016\/j.autrev.2022.103264_bb0385","doi-asserted-by":"crossref","first-page":"841","DOI":"10.3899\/jrheum.170541","article-title":"Rituximab in the treatment of interstitial lung disease associated with Antisynthetase syndrome: a multicenter retrospective case review","volume":"45","author":"Doyle","year":"2018","journal-title":"J Rheumatol"},{"issue":"8","key":"10.1016\/j.autrev.2022.103264_bb0390","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1093\/rheumatology\/kev004","article-title":"Long-term experience with rituximab in anti-synthetase syndrome-related interstitial lung disease","volume":"54","author":"Andersson","year":"2015","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2022.103264_bb0395","article-title":"Efficacy of rituximab in refractory inflammatory myopathies associated with anti-Synthetase auto-antibodies: an open-label","author":"Allenbach","year":"2015","journal-title":"Phase II Trial"},{"issue":"8","key":"10.1016\/j.autrev.2022.103264_bb0400","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.3899\/jrheum.150844","article-title":"Rituximab in the treatment of Jo1 antibody-associated Antisynthetase syndrome: anti-Ro52 positivity as a marker for severity and treatment response","volume":"43","author":"Bauhammer","year":"2016","journal-title":"J Rheumatol"},{"issue":"11","key":"10.1016\/j.autrev.2022.103264_bb0405","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.3899\/jrheum.190505","article-title":"Rituximab and cyclophosphamide in Antisynthetase syndrome-related interstitial lung disease: an observational retrospective study","volume":"47","author":"Langlois","year":"2020","journal-title":"J Rheumatol"},{"issue":"1","key":"10.1016\/j.autrev.2022.103264_bb0410","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13063-017-2016-2","article-title":"Rituximab versus cyclophosphamide for the treatment of connective tissue disease associated interstitial lung disease (RECITAL): study protocol for a randomised controlled trial","volume":"18","author":"Saunders","year":"2017","journal-title":"Trials"},{"issue":"7","key":"10.1016\/j.autrev.2022.103264_bb0415","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1001\/archdermatol.2010.142","article-title":"Tumor necrosis factor inhibitor-associated dermatomyositis","volume":"146","author":"Klein","year":"2010","journal-title":"Arch Dermatol"},{"issue":"10","key":"10.1016\/j.autrev.2022.103264_bb0420","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1007\/s00296-012-2653-4","article-title":"Efficacy of infliximab in the treatment for dermatomyositis with acute interstitial pneumonia: a study of fourteen cases and literature review","volume":"33","author":"Chen","year":"2013","journal-title":"Rheumatol Int"},{"issue":"4","key":"10.1016\/j.autrev.2022.103264_bb0425","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1093\/rheumatology\/keh079","article-title":"Refractory polymyositis responding to infliximab: extended follow-up","volume":"43","author":"Labioche","year":"2004","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"10.1016\/j.autrev.2022.103264_bb0430","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1093\/rheumatology\/ket365","article-title":"Successful treatment of calcinosis with infliximab in a patient with systemic sclerosis\/myositis overlap syndrome","volume":"53","author":"Tosounidou","year":"2014","journal-title":"Rheumatology (Oxford)"},{"issue":"8","key":"10.1016\/j.autrev.2022.103264_bb0435","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1097\/CM9.0000000000001235","article-title":"Successful treatment with tocilizumab in a patient with rapidly progressive interstitial lung disease with positive anti-melanoma differentiation-associated gene-5 antibody","volume":"134","author":"Teng","year":"2020","journal-title":"Chin Med J"},{"issue":"3","key":"10.1016\/j.autrev.2022.103264_bb0440","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.jbspin.2007.07.010","article-title":"Antisynthetase syndrome with refractory polyarthritis and fever successfully treated with the IL-1 receptor antagonist, anakinra: a case report","volume":"75","author":"Furlan","year":"2008","journal-title":"Joint Bone Spine"},{"issue":"7","key":"10.1016\/j.autrev.2022.103264_bb0445","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1093\/rheumatology\/keh226","article-title":"Successful treatment of alveolar hypoventilation due to dermatomyositis with anti-tumour necrosis factor-alpha","volume":"43","author":"Korkmaz","year":"2004","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"10.1016\/j.autrev.2022.103264_bb0450","first-page":"225","article-title":"A case of macrophage activation syndrome in a patient with anti-synthetase syndrome","volume":"Jun. 2021","author":"Ahmad","year":"2021","journal-title":"Oxf Med Case Reports"},{"key":"10.1016\/j.autrev.2022.103264_bb0455","article-title":"Case report: fatal case of macrophage activation syndrome (MAS) in a patient with dermatomyositis and cytomegalovirus (CMV) viraemia","volume":"Jul. 2018","author":"Lange","year":"2018","journal-title":"BMJ Case Rep"},{"issue":"1","key":"10.1016\/j.autrev.2022.103264_bb0460","doi-asserted-by":"crossref","DOI":"10.1186\/s12891-015-0710-3","article-title":"Biologic predictors of clinical improvement in rituximab-treated refractory myositis","volume":"16","author":"Reed","year":"2015","journal-title":"BMC Musculoskelet Disord"},{"issue":"6","key":"10.1016\/j.autrev.2022.103264_bb0465","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1093\/rheumatology\/kev444","article-title":"Autoantibody levels in myositis patients correlate with clinical response during B cell depletion with rituximab","volume":"55","author":"Aggarwal","year":"2016","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"10.1016\/j.autrev.2022.103264_bb0470","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1002\/art.38270","article-title":"Predictors of clinical improvement in rituximab-treated refractory adult and juvenile dermatomyositis and adult polymyositis","volume":"66","author":"Aggarwal","year":"2014","journal-title":"Arthritis Rheum"},{"issue":"7","key":"10.1016\/j.autrev.2022.103264_bb0475","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1093\/rheumatology\/key450","article-title":"Efficacy and safety of rituximab in anti-synthetase antibody positive and negative subjects with idiopathic inflammatory myopathy: a registry-based study","volume":"58","author":"Leclair","year":"2019","journal-title":"Rheumatology"},{"issue":"7","key":"10.1016\/j.autrev.2022.103264_bb0480","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1136\/ard.2005.045898","article-title":"Rituximab in the treatment of antisynthetase syndrome","volume":"65","author":"Brulhart","year":"2006","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.autrev.2022.103264_bb0485","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1186\/2049-6958-6-3-183","article-title":"Rituximab treatment in a case of antisynthetase syndrome with severe interstitial lung disease and acute respiratory failure","volume":"6","author":"Zappa","year":"2011","journal-title":"Multidiscip Respir Med"},{"issue":"1","key":"10.1016\/j.autrev.2022.103264_bb0490","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1365-2141.2010.08076.x","article-title":"The effect of rituximab on humoral and cell mediated immunity and infection in the treatment of autoimmune diseases","volume":"149","author":"Cooper","year":"2010","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.autrev.2022.103264_bb0495","first-page":"1","article-title":"Successful rituximab treatment for severe rapidly progressive interstitial lung disease with anti-MDA5 antibody-positive juvenile dermatomyositis: a case report and literature review","volume":"20","author":"Nishi","year":"2022","journal-title":"Pediatr Rheumatol"},{"key":"10.1016\/j.autrev.2022.103264_bb0500","article-title":"Acute lung injury after plasma exchange in a patient with anti-MDA5 antibody-positive, rapidly progressive, interstitial lung disease:A case report","volume":"29","author":"Kagawa","year":"2020","journal-title":"Respir Med Case Rep"},{"issue":"10","key":"10.1016\/j.autrev.2022.103264_bb0505","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2340\/00015555-3481","article-title":"Unexpected hair regrowth in a patient with longstanding alopecia universalis during treatment of recalcitrant dermatomyositis with the janus kinase inhibitor ruxolitinib","volume":"100","author":"Fetter","year":"2020","journal-title":"Acta Derm Venereol"},{"issue":"9","key":"10.1016\/j.autrev.2022.103264_bb0510","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1093\/rheumatology\/keh700","article-title":"Fatal Mycobacterium peregrinum pneumonia in refractory polymyositis treated with infliximab","volume":"44","author":"Marie","year":"2005","journal-title":"Rheumatology (Oxford)"},{"issue":"7","key":"10.1016\/j.autrev.2022.103264_bb0515","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1001\/archdermatol.2011.49","article-title":"Double trouble: therapeutic challenges in patients with both juvenile dermatomyositis and psoriasis","volume":"147","author":"Kim","year":"2011","journal-title":"Arch Dermatol"},{"issue":"6","key":"10.1016\/j.autrev.2022.103264_bb0520","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.3899\/jrheum.111126","article-title":"Progressive multifocal leukoencephalopathy in a patient with polymyositis: case report and literature review","volume":"39","author":"Dastmalchi","year":"2012","journal-title":"J Rheumatol"},{"issue":"3","key":"10.1016\/j.autrev.2022.103264_bb0525","doi-asserted-by":"crossref","first-page":"e13","DOI":"10.1016\/j.ejim.2011.01.001","article-title":"Progressive multifocal leukoencephalopathy in refractory polymyositis treated with rituximab","volume":"22","author":"Marie","year":"2011","journal-title":"Eur J Intern Med"},{"issue":"5","key":"10.1016\/j.autrev.2022.103264_bb0530","doi-asserted-by":"crossref","first-page":"519","DOI":"10.2169\/internalmedicine.54.2748","article-title":"Atypical progressive multifocal leukoencephalopathy in a patient with Antisynthetase syndrome","volume":"54","author":"Belhassen-Garcia","year":"2015","journal-title":"Intern Med"},{"issue":"5","key":"10.1016\/j.autrev.2022.103264_bb0535","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/nrrheum.2018.48","article-title":"Risk factors and disease mechanisms in myositis","volume":"14","author":"Miller","year":"2018","journal-title":"Nat Rev Rheumatol"},{"issue":"1","key":"10.1016\/j.autrev.2022.103264_bb0540","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1111\/ene.13357","article-title":"A review of inflammatory idiopathic myopathy focusing on polymyositis","volume":"25","author":"Clark","year":"2018","journal-title":"Eur J Neurol"},{"issue":"8","key":"10.1016\/j.autrev.2022.103264_bb0545","doi-asserted-by":"crossref","first-page":"2016","DOI":"10.1002\/art.39650","article-title":"CD41 and CD81 CD28 null T cells are cytotoxic to autologous muscle cells in patients with polymyositis","volume":"68","author":"Pandya","year":"2016","journal-title":"Arthritis Rheum"},{"issue":"1\u20132","key":"10.1016\/j.autrev.2022.103264_bb0550","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.jneuroim.2010.03.013","article-title":"FOXP3+ T regulatory cells in idiopathic inflammatory myopathies","volume":"225","author":"Waschbisch","year":"2010","journal-title":"J Neuroimmunol"},{"issue":"5","key":"10.1016\/j.autrev.2022.103264_bb0555","first-page":"887","article-title":"Clinical outcome following B cell depletion therapy in eight patients with refractory idiopathic inflammatory myopathy","volume":"26","author":"Sultan","year":"2008","journal-title":"Clin Exp Rheumatol"},{"issue":"11","key":"10.1016\/j.autrev.2022.103264_bb0560","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1212\/01.wnl.0000187124.92826.20","article-title":"Plasma cells in muscle in inclusion body myositis and polymyositis","volume":"65","author":"Greenberg","year":"2005","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.autrev.2022.103264_bb0565","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1080\/08916930600622256","article-title":"Cytokines in idiopathic inflammatory myopathies","volume":"39","author":"Salomonsson","year":"2006","journal-title":"Autoimmunity"},{"issue":"11","key":"10.1016\/j.autrev.2022.103264_bb0570","doi-asserted-by":"crossref","first-page":"3436","DOI":"10.1002\/art.24936","article-title":"Interleukin-6 and type I interferon-regulated genes and chemokines mark disease activity in dermatomyositis","volume":"60","author":"Bilgic","year":"2009","journal-title":"Arthritis Rheum"},{"issue":"2","key":"10.1016\/j.autrev.2022.103264_bb0575","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s00296-019-04467-6","article-title":"Biologic therapy in the idiopathic inflammatory myopathies","volume":"40","author":"Khoo","year":"2020","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.autrev.2022.103264_bb0580","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/179180","article-title":"New onset of dermatomyositis\/polymyositis during anti-TNF-\u03b1 therapies: a systematic literature review","volume":"2014","author":"Brunasso","year":"2014","journal-title":"ScientificWorldJournal"},{"issue":"Suppl. 1","key":"10.1016\/j.autrev.2022.103264_bb0585","article-title":"Type 1 interferons and myositis","volume":"12","author":"Greenberg","year":"2010","journal-title":"Arthritis Res Ther"},{"issue":"2","key":"10.1016\/j.autrev.2022.103264_bb0590","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1002\/art.22388","article-title":"Immunolocalization of interleukin-1 receptors in the sarcolemma and nuclei of skeletal muscle in patients with idiopathic inflammatory myopathies","volume":"56","author":"Grundtman","year":"2007","journal-title":"Arthritis Rheum"},{"issue":"2","key":"10.1016\/j.autrev.2022.103264_bb0595","doi-asserted-by":"crossref","first-page":"128","DOI":"10.2169\/internalmedicine.39.128","article-title":"Abnormal IL-1 receptor antagonist production in patients with polymyositis and dermatomyositis","volume":"39","author":"Son","year":"2000","journal-title":"Intern Med"},{"issue":"1","key":"10.1016\/j.autrev.2022.103264_bb0600","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1172\/JCI118398","article-title":"Interleukin 6 receptor antibody inhibits muscle atrophy and modulates proteolytic systems in interleukin 6 transgenic mice","volume":"97","author":"Tsujinaka","year":"1996","journal-title":"J Clin Invest"},{"issue":"2","key":"10.1016\/j.autrev.2022.103264_bb0605","first-page":"393","article-title":"Interleukin-6 and cachexia in ApcMin\/+ mice","volume":"294","author":"Baltgalvis","year":"2008","journal-title":"Am J Phys Regul Integr Comp Phys"},{"issue":"17","key":"10.1016\/j.autrev.2022.103264_bb0610","doi-asserted-by":"crossref","first-page":"4131","DOI":"10.1111\/febs.12338","article-title":"Interleukin-6 myokine signaling in skeletal muscle: a double-edged sword?","volume":"280","author":"Mu\u00f1oz-C\u00e1noves","year":"2013","journal-title":"FEBS J"},{"issue":"12","key":"10.1016\/j.autrev.2022.103264_bb0615","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.1093\/rheumatology\/keu258","article-title":"Cytokine profiles in polymyositis and dermatomyositis complicated by rapidly progressive or chronic interstitial lung disease","volume":"53","author":"Gono","year":"2014","journal-title":"Rheumatology (Oxford)"},{"issue":"1\u20132","key":"10.1016\/j.autrev.2022.103264_bb0620","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.jneuroim.2006.03.026","article-title":"IL-6-deficient mice show impaired inflammatory response in a model of myosin-induced experimental myositis","volume":"176","author":"Scuderi","year":"2006","journal-title":"J Neuroimmunol"},{"issue":"1","key":"10.1016\/j.autrev.2022.103264_bb0625","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s12016-016-8530-2","article-title":"Modern therapies for idiopathic inflammatory myopathies (IIMs): role of biologics","volume":"52","author":"Moghadam-Kia","year":"2017","journal-title":"Clin Rev Allergy Immunol"},{"issue":"6","key":"10.1016\/j.autrev.2022.103264_bb0630","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1097\/BOR.0000000000000744","article-title":"Cytokines and inflammatory mediators as promising markers of polymyositis\/dermatomyositis","volume":"32","author":"Cerezo","year":"2020","journal-title":"Curr Opin Rheumatol"},{"issue":"11","key":"10.1016\/j.autrev.2022.103264_bb0635","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1111\/j.1365-4632.2009.04164.x","article-title":"A histopathologic study of mechanic\u2019s hands associated with dermatomyositis: a report of five cases","volume":"48","author":"Mii","year":"2009","journal-title":"Int J Dermatol"},{"issue":"3","key":"10.1016\/j.autrev.2022.103264_bb0640","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1038\/gene.2011.61","article-title":"Relationship between disease activity and type 1 interferon- and other cytokine-inducible gene expression in blood in dermatomyositis and polymyositis","volume":"13","author":"Greenberg","year":"2012","journal-title":"Genes Immun"},{"issue":"4","key":"10.1016\/j.autrev.2022.103264_bb0645","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1007\/s00401-017-1731-9","article-title":"IFN-\u03b2-induced reactive oxygen species and mitochondrial damage contribute to muscle impairment and inflammation maintenance in dermatomyositis","volume":"134","author":"Meyer","year":"2017","journal-title":"Acta Neuropathol"},{"issue":"8","key":"10.1016\/j.autrev.2022.103264_bb0650","doi-asserted-by":"crossref","first-page":"4693","DOI":"10.4049\/jimmunol.1002631","article-title":"IFN-\u03b1 mediates the development of autoimmunity both by direct tissue toxicity and through immune cell recruitment mechanisms","volume":"186","author":"Akeno","year":"2011","journal-title":"J Immunol"},{"issue":"3","key":"10.1016\/j.autrev.2022.103264_bb0655","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1007\/s00125-017-4536-4","article-title":"IFN-\u03b1 induces a preferential long-lasting expression of MHC class I in human pancreatic beta cells","volume":"61","author":"Coomans de Brach\u00e8ne","year":"2018","journal-title":"Diabetologia"},{"issue":"4","key":"10.1016\/j.autrev.2022.103264_bb0660","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1093\/rheumatology\/ket413","article-title":"Suppression of soluble T cell-associated proteins by an anti-interferon-\u03b1 monoclonal antibody in adult patients with dermatomyositis or polymyositis","volume":"53","author":"Guo","year":"2014","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"10.1016\/j.autrev.2022.103264_bb0665","doi-asserted-by":"crossref","first-page":"E8","DOI":"10.1093\/brain\/awz005","article-title":"Janus kinase 1\/2 inhibition with baricitinib in the treatment of juvenile dermatomyositis","volume":"142","author":"Papadopoulou","year":"2019","journal-title":"Brain"},{"issue":"2","key":"10.1016\/j.autrev.2022.103264_bb0670","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.jdcr.2018.11.019","article-title":"Apremilast as a potential treatment for moderate to severe dermatomyositis: a retrospective study of 3 patients","volume":"5","author":"Bitar","year":"2019","journal-title":"JAAD Case Rep"},{"issue":"2","key":"10.1016\/j.autrev.2022.103264_bb0675","doi-asserted-by":"crossref","first-page":"171","DOI":"10.3109\/03009742.2013.863968","article-title":"Severe macrophage activation syndrome and central nervous system involvement in juvenile dermatomyositis","volume":"43","author":"Lilleby","year":"2014","journal-title":"Scand J Rheumatol"},{"issue":"3","key":"10.1016\/j.autrev.2022.103264_bb0680","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1136\/annrheumdis-2020-218690","article-title":"Janus kinase (JAK) inhibition with baricitinib in refractory juvenile dermatomyositis","volume":"80","author":"Kim","year":"2021","journal-title":"Ann Rheum Dis"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997222002348?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997222002348?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T21:26:56Z","timestamp":1761600416000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997222002348"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":136,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["S1568997222002348"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2022.103264","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The role of bDMARDs in idiopathic inflammatory myopathies: A systematic literature review","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2022.103264","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"103264"}}